Source: http://www.alz-pharma.com/
Lyon, France, September 12, 2016: Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces it will present preclinical results from its I-HBD1 program in osteoporosis during the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Atlanta on September 16-19, 2016.
Alizé’s I-HBD1 program focuses on a new peptide derived from a physiological protein, IGFBP-2 (Insulin-like Growth Factor Binding Protein-2), as a new bone anabolic agent. Scientific work led by Dr David Clemmons from the University of North Carolina at Chapel Hill (USA) and Dr Clifford Rosen from the University of Maine (USA) has established that IGFBP2 plays a key physiological role in the differentiation of osteoblasts, the cells responsible for bone formation. I-HBD1, a short peptide fragment derived from IGFBP-2, replicates the anabolic effects of IGFBP-2 on bone. It is intended to be developed as a new therapeutic approach for osteoporosis and some rare metabolic diseases associated with impaired bone formation.
Alizé Pharma III is conducting the I-HBD1 project in collaboration with New Paradigm Therapeutics, a spin-off company from the University of North Carolina at Chapel Hill founded by Dr. David Clemmons.
Read more: http://www.alz-pharma.com/actualite/alize-pharma-iii-presents-preclinical-results-from-its-i-hbd1-program-at-the-annual-meeting-of-the-american-society-for-bone-and-mineral-research